Literature DB >> 27821488

Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer.

Étienne Audet-Walsh1, Tracey Yee1, Shawn McGuirk1,2, Mathieu Vernier1, Carlo Ouellet1, Julie St-Pierre1,2, Vincent Giguère3,2,4.   

Abstract

How androgen signaling contributes to the oncometabolic state of prostate cancer remains unclear. Here, we show how the estrogen-related receptor γ (ERRγ) negatively controls mitochondrial respiration in prostate cancer cells. Sustained treatment of prostate cancer cells with androgens increased the activity of several metabolic pathways, including aerobic glycolysis, mitochondrial respiration, and lipid synthesis. An analysis of the intersection of gene expression, binding events, and motif analyses after androgen exposure identified a metabolic gene expression signature associated with the action of ERRγ. This metabolic state paralleled the loss of ERRγ expression. It occurred in both androgen-dependent and castration-resistant prostate cancer and was associated with cell proliferation. Clinically, we observed an inverse relationship between ERRγ expression and disease severity. These results illuminate a mechanism in which androgen-dependent repression of ERRγ reprograms prostate cancer cell metabolism to favor mitochondrial activity and cell proliferation. Furthermore, they rationalize strategies to reactivate ERRγ signaling as a generalized therapeutic approach to manage prostate cancer. Cancer Res; 77(2); 378-89. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27821488     DOI: 10.1158/0008-5472.CAN-16-1204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.

Authors:  Boyan Huang; Peiqiang Mu; Yan Yu; Wenya Zhu; Tianqing Jiang; Rong Deng; Gongkan Feng; Jikai Wen; Xiaofeng Zhu; Yiqun Deng
Journal:  Gastric Cancer       Date:  2020-06-11       Impact factor: 7.370

2.  Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.

Authors:  Hye-Young Nam; Darshan S Chandrashekar; Anirban Kundu; Sandeep Shelar; Eun-Young Kho; Guru Sonpavde; Gurudatta Naik; Pooja Ghatalia; Carolina B Livi; Sooryanarayana Varambally; Sunil Sudarshan
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

3.  Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.

Authors:  Yogesh M Bramhecha; Karl-Philippe Guérard; Étienne Audet-Walsh; Shaghayegh Rouzbeh; Ola Kassem; Erwan Pernet; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Maziar Divangahi; Armen G Aprikian; Simone Chevalier; Vincent Giguère; Jacques Lapointe
Journal:  Oncogene       Date:  2022-04-11       Impact factor: 9.867

Review 4.  Metabolic changes during prostate cancer development and progression.

Authors:  Alicia-Marie K Beier; Martin Puhr; Matthias B Stope; Christian Thomas; Holger H H Erb
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-23       Impact factor: 4.322

Review 5.  Transcriptional control of energy metabolism by nuclear receptors.

Authors:  Charlotte Scholtes; Vincent Giguère
Journal:  Nat Rev Mol Cell Biol       Date:  2022-05-16       Impact factor: 113.915

6.  Estrogen-Related Receptor γ Agonist DY131 Ameliorates Lipopolysaccharide-Induced Acute Liver Injury.

Authors:  Haoyang Ma; Jiaye Liu; Yang Du; Shengnan Zhang; Weidong Cao; Zhanjun Jia; Wei Gong; Aihua Zhang
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 7.  The Role of Nuclear Receptors in Prostate Cancer.

Authors:  Masaki Shiota; Naohiro Fujimoto; Eiji Kashiwagi; Masatoshi Eto
Journal:  Cells       Date:  2019-06-17       Impact factor: 6.600

8.  RNA sequencing data of human prostate cancer cells treated with androgens.

Authors:  Raghavendra Tejo Karthik Poluri; Charles Joly Beauparlant; Arnaud Droit; Étienne Audet-Walsh
Journal:  Data Brief       Date:  2019-08-09

9.  Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Authors:  Étienne Audet-Walsh; Catherine R Dufour; Tracey Yee; Fatima Z Zouanat; Ming Yan; Georges Kalloghlian; Mathieu Vernier; Maxime Caron; Guillaume Bourque; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Armen G Aprikian; Jacques Lapointe; Simone Chevalier; Vincent Giguère
Journal:  Genes Dev       Date:  2017-07-19       Impact factor: 11.361

10.  Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?

Authors:  Raghavendra Tejo Karthik Poluri; Étienne Audet-Walsh
Journal:  Front Oncol       Date:  2018-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.